tetano
Editor, Senior Moderator
Clin Transl Immunology. 2020 Feb 3;9(2):e1107. doi: 10.1002/cti2.1107. eCollection 2020. [h=1]Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults.[/h]
Kavian N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Hachim A[SUP]1,[/SUP][SUP]2[/SUP], Li AP[SUP]1,[/SUP][SUP]2[/SUP], Cohen CA[SUP]1,[/SUP][SUP]2[/SUP], Chin AW[SUP]2[/SUP], Poon LL[SUP]2[/SUP], Fang VJ[SUP]2[/SUP], Leung NH[SUP]2[/SUP], Cowling BJ[SUP]2[/SUP], Valkenburg SA[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Objectives:[/h] Enhanced inactivated influenza vaccines (eIIV) aim to increase immunogenicity and protection compared with the widely used standard IIV (S-IIV).
[h=4]Methods:[/h] We tested four vaccines in parallel, FluZone high dose, FluBlok and FluAd versus S-IIV in a randomised controlled trial of older adults and in a mouse infection model to assess immunogenicity, protection from lethal challenge and mechanisms of action.
[h=4]Results:[/h] In older adults, FluAd vaccination stimulated a superior antibody profile, including H3-HA antibodies that were elevated for up to 1 year after vaccination, higher avidity H3HA IgG and larger HA stem IgG responses. In a mouse model, FluAd also elicited an earlier and larger induction of HA stem antibodies with increased germinal centre responses and upregulation and long-term expression of B-cell switch transcription factors. Long-term cross-reactive memory responses were sustained by FluAd following lethal heterosubtypic influenza challenge, with reduced lung damage and viral loads, coinciding with increased T- and B-cell recall. Advantages were also noted for the high-dose FluZone vaccine in both humans and mice.
[h=4]Conclusion:[/h] The early, broadly reactive and long-lived antibody response of FluAd indicates a potential advantage of this vaccine, particularly in years when there is a mismatch between the vaccine strain and the circulating strain of influenza viruses.
? 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.
[h=4]KEYWORDS:[/h] B cell; HA stem; adjuvant; antibody; infection; influenza vaccine
PMID: 32025302 PMCID: PMC6997034 DOI: 10.1002/cti2.1107
Kavian N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Hachim A[SUP]1,[/SUP][SUP]2[/SUP], Li AP[SUP]1,[/SUP][SUP]2[/SUP], Cohen CA[SUP]1,[/SUP][SUP]2[/SUP], Chin AW[SUP]2[/SUP], Poon LL[SUP]2[/SUP], Fang VJ[SUP]2[/SUP], Leung NH[SUP]2[/SUP], Cowling BJ[SUP]2[/SUP], Valkenburg SA[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Objectives:[/h] Enhanced inactivated influenza vaccines (eIIV) aim to increase immunogenicity and protection compared with the widely used standard IIV (S-IIV).
[h=4]Methods:[/h] We tested four vaccines in parallel, FluZone high dose, FluBlok and FluAd versus S-IIV in a randomised controlled trial of older adults and in a mouse infection model to assess immunogenicity, protection from lethal challenge and mechanisms of action.
[h=4]Results:[/h] In older adults, FluAd vaccination stimulated a superior antibody profile, including H3-HA antibodies that were elevated for up to 1 year after vaccination, higher avidity H3HA IgG and larger HA stem IgG responses. In a mouse model, FluAd also elicited an earlier and larger induction of HA stem antibodies with increased germinal centre responses and upregulation and long-term expression of B-cell switch transcription factors. Long-term cross-reactive memory responses were sustained by FluAd following lethal heterosubtypic influenza challenge, with reduced lung damage and viral loads, coinciding with increased T- and B-cell recall. Advantages were also noted for the high-dose FluZone vaccine in both humans and mice.
[h=4]Conclusion:[/h] The early, broadly reactive and long-lived antibody response of FluAd indicates a potential advantage of this vaccine, particularly in years when there is a mismatch between the vaccine strain and the circulating strain of influenza viruses.
? 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.
[h=4]KEYWORDS:[/h] B cell; HA stem; adjuvant; antibody; infection; influenza vaccine
PMID: 32025302 PMCID: PMC6997034 DOI: 10.1002/cti2.1107